Summary
63 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 456% a year over the last 3 years.
- Out of every 100 AUD of revenue, 47 AUD is left as net profit.
- It has no debt and holds $26.9M in cash.
- The share price is below the Bulios Fair Price.
What to watch
- It earns only 5.1 AUD a year on every 100 AUD of invested capital.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapPrice against the Bulios Fair Price
P/E against the industry (Biotechnology)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 85.3 AUD for 1 AUD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (AUD)
Diluted EPS (AUD)
- Analyst estimate
Revenue grew by 146% a year over 5 years. Over the last 3 years it grew by 64% a year. Earnings per share grew by 456% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 0.75%
- Paid out of profit
- 64%
You receive 0.11 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.